JP2010514788A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2010514788A5 JP2010514788A5 JP2009544239A JP2009544239A JP2010514788A5 JP 2010514788 A5 JP2010514788 A5 JP 2010514788A5 JP 2009544239 A JP2009544239 A JP 2009544239A JP 2009544239 A JP2009544239 A JP 2009544239A JP 2010514788 A5 JP2010514788 A5 JP 2010514788A5
- Authority
- JP
- Japan
- Prior art keywords
- piperidin
- yloxy
- benzamide
- benzylpiperidin
- alkyl
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- -1 hydrate Chemical class 0.000 claims description 171
- 150000001875 compounds Chemical class 0.000 claims description 163
- 125000000217 alkyl group Chemical group 0.000 claims description 92
- KXDAEFPNCMNJSK-UHFFFAOYSA-N benzene carboxamide Natural products NC(=O)C1=CC=CC=C1 KXDAEFPNCMNJSK-UHFFFAOYSA-N 0.000 claims description 38
- 125000004093 cyano group Chemical group *C#N 0.000 claims description 32
- 125000001475 halogen functional group Chemical group 0.000 claims description 24
- 150000003839 salts Chemical class 0.000 claims description 21
- 239000012453 solvate Substances 0.000 claims description 20
- 239000000203 mixture Substances 0.000 claims description 15
- 239000000651 prodrug Substances 0.000 claims description 15
- 229940002612 prodrug Drugs 0.000 claims description 15
- 150000001204 N-oxides Chemical class 0.000 claims description 12
- 125000000876 trifluoromethoxy group Chemical group FC(F)(F)O* 0.000 claims description 12
- 125000002023 trifluoromethyl group Chemical group FC(F)(F)* 0.000 claims description 12
- 150000007942 carboxylates Chemical class 0.000 claims description 10
- 229910052736 halogen Inorganic materials 0.000 claims description 10
- 125000001072 heteroaryl group Chemical group 0.000 claims description 10
- 229910052799 carbon Inorganic materials 0.000 claims description 8
- 125000004043 oxo group Chemical group O=* 0.000 claims description 8
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 claims description 7
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims description 7
- 125000002252 acyl group Chemical group 0.000 claims description 6
- 125000003118 aryl group Chemical group 0.000 claims description 6
- 150000003857 carboxamides Chemical class 0.000 claims description 6
- 125000000449 nitro group Chemical group [O-][N+](*)=O 0.000 claims description 6
- 125000006513 pyridinyl methyl group Chemical group 0.000 claims description 6
- 125000000999 tert-butyl group Chemical group [H]C([H])([H])C(*)(C([H])([H])[H])C([H])([H])[H] 0.000 claims description 6
- 125000001797 benzyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])* 0.000 claims description 5
- 125000006575 electron-withdrawing group Chemical group 0.000 claims description 4
- 125000000592 heterocycloalkyl group Chemical group 0.000 claims description 4
- QPJVMBTYPHYUOC-UHFFFAOYSA-N methyl benzoate Chemical compound COC(=O)C1=CC=CC=C1 QPJVMBTYPHYUOC-UHFFFAOYSA-N 0.000 claims description 4
- OPZIJNBWFXUVDG-UHFFFAOYSA-N n-(1-benzylpiperidin-4-yl)-3-chloro-4-[1-[(4-methoxyphenyl)methyl]piperidin-4-yl]oxybenzamide Chemical compound C1=CC(OC)=CC=C1CN1CCC(OC=2C(=CC(=CC=2)C(=O)NC2CCN(CC=3C=CC=CC=3)CC2)Cl)CC1 OPZIJNBWFXUVDG-UHFFFAOYSA-N 0.000 claims description 4
- SJIZCVQALKMPCJ-UHFFFAOYSA-N n-(1-benzylpiperidin-4-yl)-4-(1-benzylpiperidin-4-yl)oxy-3-methoxybenzamide Chemical compound COC1=CC(C(=O)NC2CCN(CC=3C=CC=CC=3)CC2)=CC=C1OC(CC1)CCN1CC1=CC=CC=C1 SJIZCVQALKMPCJ-UHFFFAOYSA-N 0.000 claims description 4
- 125000004482 piperidin-4-yl group Chemical group N1CCC(CC1)* 0.000 claims description 4
- 125000005301 thienylmethyl group Chemical group [H]C1=C([H])C([H])=C(S1)C([H])([H])* 0.000 claims description 4
- 125000004575 3-pyrrolidinyl group Chemical group [H]N1C([H])([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 claims description 3
- 201000001320 Atherosclerosis Diseases 0.000 claims description 3
- 208000024172 Cardiovascular disease Diseases 0.000 claims description 3
- 150000004677 hydrates Chemical class 0.000 claims description 3
- 125000004484 1-methylpiperidin-4-yl group Chemical group CN1CCC(CC1)* 0.000 claims description 2
- PYPFAWVKBZFLFU-UHFFFAOYSA-N 4-[[4-[[3-fluoro-4-[1-[4-(trifluoromethyl)phenyl]piperidin-4-yl]oxybenzoyl]amino]piperidin-1-yl]methyl]benzoic acid Chemical compound C1=CC(C(=O)O)=CC=C1CN1CCC(NC(=O)C=2C=C(F)C(OC3CCN(CC3)C=3C=CC(=CC=3)C(F)(F)F)=CC=2)CC1 PYPFAWVKBZFLFU-UHFFFAOYSA-N 0.000 claims description 2
- 102100036009 5'-AMP-activated protein kinase catalytic subunit alpha-2 Human genes 0.000 claims description 2
- 229920002527 Glycogen Polymers 0.000 claims description 2
- 101000783681 Homo sapiens 5'-AMP-activated protein kinase catalytic subunit alpha-2 Proteins 0.000 claims description 2
- 230000003213 activating effect Effects 0.000 claims description 2
- 125000003725 azepanyl group Chemical group 0.000 claims description 2
- 125000004567 azetidin-3-yl group Chemical group N1CC(C1)* 0.000 claims description 2
- 125000002393 azetidinyl group Chemical group 0.000 claims description 2
- 125000000753 cycloalkyl group Chemical group 0.000 claims description 2
- 235000014113 dietary fatty acids Nutrition 0.000 claims description 2
- 239000003085 diluting agent Substances 0.000 claims description 2
- 239000003937 drug carrier Substances 0.000 claims description 2
- 229930195729 fatty acid Natural products 0.000 claims description 2
- 239000000194 fatty acid Substances 0.000 claims description 2
- 150000004665 fatty acids Chemical class 0.000 claims description 2
- 125000002541 furyl group Chemical group 0.000 claims description 2
- 230000004190 glucose uptake Effects 0.000 claims description 2
- 229940096919 glycogen Drugs 0.000 claims description 2
- 229940095102 methyl benzoate Drugs 0.000 claims description 2
- OSEGNJLBTIAZAR-UHFFFAOYSA-N n-(1-benzylpiperidin-4-yl)-4-(1-benzylpiperidin-4-yl)oxy-3-chlorobenzamide Chemical compound ClC1=CC(C(=O)NC2CCN(CC=3C=CC=CC=3)CC2)=CC=C1OC(CC1)CCN1CC1=CC=CC=C1 OSEGNJLBTIAZAR-UHFFFAOYSA-N 0.000 claims description 2
- ZSSQHQZDGFFADT-UHFFFAOYSA-N n-(1-benzylpiperidin-4-yl)-4-[1-[(3,4-dichlorophenyl)methyl]piperidin-4-yl]oxy-3-fluorobenzamide Chemical compound FC1=CC(C(=O)NC2CCN(CC=3C=CC=CC=3)CC2)=CC=C1OC(CC1)CCN1CC1=CC=C(Cl)C(Cl)=C1 ZSSQHQZDGFFADT-UHFFFAOYSA-N 0.000 claims description 2
- VTAPBBBNOFCMJE-UHFFFAOYSA-N n-(1-benzylpiperidin-4-yl)-4-[1-[(3,4-difluorophenyl)methyl]piperidin-4-yl]oxy-3-fluorobenzamide Chemical compound C1=C(F)C(F)=CC=C1CN1CCC(OC=2C(=CC(=CC=2)C(=O)NC2CCN(CC=3C=CC=CC=3)CC2)F)CC1 VTAPBBBNOFCMJE-UHFFFAOYSA-N 0.000 claims description 2
- WPVQGPSAFVQBTQ-UHFFFAOYSA-N n-(1-benzylpiperidin-4-yl)-4-[1-[(4-chlorophenyl)methyl]piperidin-4-yl]oxy-3-fluorobenzamide Chemical compound FC1=CC(C(=O)NC2CCN(CC=3C=CC=CC=3)CC2)=CC=C1OC(CC1)CCN1CC1=CC=C(Cl)C=C1 WPVQGPSAFVQBTQ-UHFFFAOYSA-N 0.000 claims description 2
- FEMJUIILXCLATR-UHFFFAOYSA-N n-(1-benzylpiperidin-4-yl)-4-[1-[(4-cyanophenyl)methyl]piperidin-4-yl]oxy-3-fluorobenzamide Chemical compound FC1=CC(C(=O)NC2CCN(CC=3C=CC=CC=3)CC2)=CC=C1OC(CC1)CCN1CC1=CC=C(C#N)C=C1 FEMJUIILXCLATR-UHFFFAOYSA-N 0.000 claims description 2
- RSVKHYKCXSKQMH-UHFFFAOYSA-N n-[1-[(4-chlorophenyl)methyl]piperidin-4-yl]-4-[1-(4-cyanophenyl)piperidin-4-yl]oxy-3-fluorobenzamide Chemical compound FC1=CC(C(=O)NC2CCN(CC=3C=CC(Cl)=CC=3)CC2)=CC=C1OC(CC1)CCN1C1=CC=C(C#N)C=C1 RSVKHYKCXSKQMH-UHFFFAOYSA-N 0.000 claims description 2
- FTQQFCXRUSWUMF-UHFFFAOYSA-N n-[1-[(4-chlorophenyl)methyl]piperidin-4-yl]-4-[1-[(3,4-dichlorophenyl)methyl]piperidin-4-yl]oxy-3-fluorobenzamide Chemical compound FC1=CC(C(=O)NC2CCN(CC=3C=CC(Cl)=CC=3)CC2)=CC=C1OC(CC1)CCN1CC1=CC=C(Cl)C(Cl)=C1 FTQQFCXRUSWUMF-UHFFFAOYSA-N 0.000 claims description 2
- UIOUEJIAZRRPMS-UHFFFAOYSA-N n-[1-[(4-chlorophenyl)methyl]piperidin-4-yl]-4-[1-[(3,4-difluorophenyl)methyl]piperidin-4-yl]oxy-3-fluorobenzamide Chemical compound C1=C(F)C(F)=CC=C1CN1CCC(OC=2C(=CC(=CC=2)C(=O)NC2CCN(CC=3C=CC(Cl)=CC=3)CC2)F)CC1 UIOUEJIAZRRPMS-UHFFFAOYSA-N 0.000 claims description 2
- QFKXALBARODOIK-UHFFFAOYSA-N n-[1-[(4-chlorophenyl)methyl]piperidin-4-yl]-4-[1-[(4-chlorophenyl)methyl]piperidin-4-yl]oxy-3-fluorobenzamide Chemical compound FC1=CC(C(=O)NC2CCN(CC=3C=CC(Cl)=CC=3)CC2)=CC=C1OC(CC1)CCN1CC1=CC=C(Cl)C=C1 QFKXALBARODOIK-UHFFFAOYSA-N 0.000 claims description 2
- WHGMTCQFUXQDID-UHFFFAOYSA-N n-[1-[(4-chlorophenyl)methyl]piperidin-4-yl]-4-[1-[(4-cyanophenyl)methyl]piperidin-4-yl]oxy-3-fluorobenzamide Chemical compound FC1=CC(C(=O)NC2CCN(CC=3C=CC(Cl)=CC=3)CC2)=CC=C1OC(CC1)CCN1CC1=CC=C(C#N)C=C1 WHGMTCQFUXQDID-UHFFFAOYSA-N 0.000 claims description 2
- OESUCOSKWSDWGA-UHFFFAOYSA-N n-[1-[(4-cyanophenyl)methyl]piperidin-4-yl]-4-[1-(4-cyanophenyl)piperidin-4-yl]oxy-3-fluorobenzamide Chemical compound FC1=CC(C(=O)NC2CCN(CC=3C=CC(=CC=3)C#N)CC2)=CC=C1OC(CC1)CCN1C1=CC=C(C#N)C=C1 OESUCOSKWSDWGA-UHFFFAOYSA-N 0.000 claims description 2
- 230000003647 oxidation Effects 0.000 claims description 2
- 238000007254 oxidation reaction Methods 0.000 claims description 2
- 230000037361 pathway Effects 0.000 claims description 2
- 239000008194 pharmaceutical composition Substances 0.000 claims description 2
- 239000000546 pharmaceutical excipient Substances 0.000 claims description 2
- 125000003386 piperidinyl group Chemical group 0.000 claims description 2
- 125000004076 pyridyl group Chemical group 0.000 claims description 2
- 125000000719 pyrrolidinyl group Chemical group 0.000 claims description 2
- 125000003107 substituted aryl group Chemical group 0.000 claims description 2
- 125000005346 substituted cycloalkyl group Chemical group 0.000 claims description 2
- 125000001544 thienyl group Chemical group 0.000 claims description 2
- UFTFJSFQGQCHQW-UHFFFAOYSA-N triformin Chemical compound O=COCC(OC=O)COC=O UFTFJSFQGQCHQW-UHFFFAOYSA-N 0.000 claims description 2
- 208000001072 type 2 diabetes mellitus Diseases 0.000 claims description 2
- 125000002733 (C1-C6) fluoroalkyl group Chemical group 0.000 claims 3
- 125000006187 phenyl benzyl group Chemical group 0.000 claims 1
- 239000002904 solvent Substances 0.000 claims 1
- 125000001424 substituent group Chemical group 0.000 claims 1
- 0 CC*(C1)CN(*)*CC(C)C*1OC(C=C1)=CC(C)(C)C=C1C(N(*)*)=O Chemical compound CC*(C1)CN(*)*CC(C)C*1OC(C=C1)=CC(C)(C)C=C1C(N(*)*)=O 0.000 description 35
- 238000000034 method Methods 0.000 description 13
- 125000003709 fluoroalkyl group Chemical group 0.000 description 12
- 238000006467 substitution reaction Methods 0.000 description 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 1
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US88231206P | 2006-12-28 | 2006-12-28 | |
| US60/882,312 | 2006-12-28 | ||
| US98871907P | 2007-11-16 | 2007-11-16 | |
| US60/988,719 | 2007-11-16 | ||
| PCT/US2007/088742 WO2008083124A1 (en) | 2006-12-28 | 2007-12-21 | N-substituted-heterocycloalkyloxybenzamide compounds and methods of use |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2010514788A JP2010514788A (ja) | 2010-05-06 |
| JP2010514788A5 true JP2010514788A5 (https=) | 2012-01-26 |
| JP5650404B2 JP5650404B2 (ja) | 2015-01-07 |
Family
ID=39204919
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2009544239A Expired - Fee Related JP5650404B2 (ja) | 2006-12-28 | 2007-12-21 | Ｎ−置換−ヘテロシクロアルキルオキシベンズアミド化合物およびその使用方法 |
Country Status (6)
| Country | Link |
|---|---|
| US (3) | US8012955B2 (https=) |
| EP (1) | EP2079694B1 (https=) |
| JP (1) | JP5650404B2 (https=) |
| CA (1) | CA2674237C (https=) |
| ES (1) | ES2627221T3 (https=) |
| WO (1) | WO2008083124A1 (https=) |
Families Citing this family (32)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| BRPI0820171B8 (pt) * | 2007-11-16 | 2021-05-25 | Rigel Pharmaceuticals Inc | compostos de carboxamida, sulfonamida e amina para distúrbios metabólicos, composição farmacêutica, e, uso dos mesmos |
| CA2707047C (en) | 2007-12-12 | 2017-11-28 | Rigel Pharmaceuticals, Inc. | Carboxamide, sulfonamide and amine compounds for metabolic disorders |
| MX2010011288A (es) * | 2008-04-23 | 2010-11-09 | Rigel Pharmaceuticals Inc | Compuestos de carboxamida para el tratamiento de trastornos metabolicos. |
| CN102365275B (zh) * | 2009-01-28 | 2014-09-24 | 里格尔药品股份有限公司 | 羧酰胺化合物及其使用方法 |
| GB0912975D0 (en) * | 2009-07-24 | 2009-09-02 | Syngenta Ltd | Formulations |
| WO2011107494A1 (de) | 2010-03-03 | 2011-09-09 | Sanofi | Neue aromatische glykosidderivate, diese verbindungen enthaltende arzneimittel und deren verwendung |
| WO2011123681A1 (en) | 2010-03-31 | 2011-10-06 | Rigel Pharmaceuticals, Inc. | Methods for using carboxamide, sulfonamide and amine compounds |
| WO2011142359A1 (ja) * | 2010-05-10 | 2011-11-17 | 日産化学工業株式会社 | スピロ化合物及びアディポネクチン受容体活性化薬 |
| WO2011157827A1 (de) | 2010-06-18 | 2011-12-22 | Sanofi | Azolopyridin-3-on-derivate als inhibitoren von lipasen und phospholipasen |
| US8530413B2 (en) | 2010-06-21 | 2013-09-10 | Sanofi | Heterocyclically substituted methoxyphenyl derivatives with an oxo group, processes for preparation thereof and use thereof as medicaments |
| TW201215388A (en) | 2010-07-05 | 2012-04-16 | Sanofi Sa | (2-aryloxyacetylamino)phenylpropionic acid derivatives, processes for preparation thereof and use thereof as medicaments |
| TW201221505A (en) | 2010-07-05 | 2012-06-01 | Sanofi Sa | Aryloxyalkylene-substituted hydroxyphenylhexynoic acids, process for preparation thereof and use thereof as a medicament |
| TW201215387A (en) | 2010-07-05 | 2012-04-16 | Sanofi Aventis | Spirocyclically substituted 1,3-propane dioxide derivatives, processes for preparation thereof and use thereof as a medicament |
| US8697911B2 (en) | 2010-07-07 | 2014-04-15 | Boehringer Ingelheim International Gmbh | Rho kinase inhibitors |
| US9079880B2 (en) | 2010-07-07 | 2015-07-14 | Boehringer Ingelheim International Gmbh | Rho kinase inhibitors |
| BR112013002112B1 (pt) | 2010-07-29 | 2021-04-06 | Rigel Pharmaceuticals, Inc. | Composto, composição farmacêutica, e, uso de um composto, ou de um respectivo sal farmaceuticamente aceitável, ou de uma composição |
| EP2630144B1 (en) | 2010-10-19 | 2016-09-07 | Boehringer Ingelheim International GmbH | Rho kinase inhibitors |
| US9005909B2 (en) | 2011-01-06 | 2015-04-14 | Rigel Pharmaceuticals, Inc. | Whole blood assay for measuring AMPK activation |
| WO2013037390A1 (en) | 2011-09-12 | 2013-03-21 | Sanofi | 6-(4-hydroxy-phenyl)-3-styryl-1h-pyrazolo[3,4-b]pyridine-4-carboxylic acid amide derivatives as kinase inhibitors |
| EP2760862B1 (en) | 2011-09-27 | 2015-10-21 | Sanofi | 6-(4-hydroxy-phenyl)-3-alkyl-1h-pyrazolo[3,4-b]pyridine-4-carboxylic acid amide derivatives as kinase inhibitors |
| US9409884B2 (en) | 2012-02-01 | 2016-08-09 | Rigel Pharmaceuticals, Inc. | 5- or 6-substituted benzofuran-2-carboxamide compounds and methods for using them |
| US8889730B2 (en) | 2012-04-10 | 2014-11-18 | Pfizer Inc. | Indole and indazole compounds that activate AMPK |
| WO2014134391A1 (en) | 2013-02-28 | 2014-09-04 | Bristol-Myers Squibb Company | Phenylpyrazole derivatives as potent rock1 and rock2 inhibitors |
| AR094929A1 (es) | 2013-02-28 | 2015-09-09 | Bristol Myers Squibb Co | Derivados de fenilpirazol como inhibidores potentes de rock1 y rock2 |
| JP6064062B2 (ja) | 2013-03-15 | 2017-01-18 | ファイザー・インク | Ａｍｐｋを活性化させるインダゾール化合物 |
| US20160214967A1 (en) | 2013-09-30 | 2016-07-28 | The University Of Tokyo | Activator of adiponectin receptor |
| EP3102198B1 (en) | 2014-02-06 | 2020-08-26 | Merck Sharp & Dohme Corp. | Antidiabetic compounds |
| US9832291B2 (en) | 2015-01-12 | 2017-11-28 | Cisco Technology, Inc. | Auto-configurable transport stack |
| CN104803914B (zh) * | 2015-03-05 | 2017-11-14 | 成都理工大学 | 作为Rho激酶抑制剂的六氢氮杂卓氧基苯甲酰胺类化合物 |
| CN110372638B (zh) * | 2018-04-13 | 2023-09-22 | 中国药科大学 | 哌嗪类ampk激动剂及其医药用途 |
| WO2021236617A1 (en) | 2020-05-19 | 2021-11-25 | Kallyope, Inc. | Ampk activators |
| CA3183575A1 (en) | 2020-06-26 | 2021-12-30 | Iyassu Sebhat | Ampk activators |
Family Cites Families (71)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB8406906D0 (en) | 1984-03-16 | 1984-04-18 | Akzo Nv | Benzo-thiazole and benzothiophene derivatives |
| JPH0784462B2 (ja) | 1986-07-25 | 1995-09-13 | 日清製粉株式会社 | ベンゾイミダゾ−ル誘導体 |
| GB9816837D0 (en) | 1998-08-04 | 1998-09-30 | Zeneca Ltd | Amide derivatives |
| US7772432B2 (en) | 1991-09-19 | 2010-08-10 | Astrazeneca Ab | Amidobenzamide derivatives which are useful as cytokine inhibitors |
| US5438064A (en) | 1991-12-23 | 1995-08-01 | American Home Products Corporation | Derivatives of 4-anilinoquinoline-3-carboxamide as analgesic agents |
| US5332732A (en) | 1992-09-11 | 1994-07-26 | Mcneilab, Inc. | Thiophene and pyridine antipsychotic agents |
| ATE216580T1 (de) | 1993-07-16 | 2002-05-15 | Merck & Co Inc | Benzoxazinon- und benzopyrimidinon- piperidinyl- verbindungen als tokolytische oxytocin-rezeptor- antagonisten |
| HU221138B1 (en) | 1994-08-30 | 2002-08-28 | Sankyo Co | Condensed isoxazolyloxy- and -thioalkylamine derivatives, process for the preparation thereof and pharmaceutical compositions containing them |
| FR2738569B1 (fr) | 1995-09-12 | 1997-11-28 | Pf Medicament | Nouveaux derives naphtamide de 3 beta-amino azabicyclo octane ou nonane, leur procede de preparation, leur utilisation a titre de medicament antipsychotique |
| CA2328927C (en) | 1998-05-15 | 2008-02-19 | Astrazeneca Ab | Benzamide derivatives for the treatment of diseases mediated by cytokines |
| CA2342251A1 (en) | 1998-08-28 | 2000-03-09 | Scios Inc. | Use of piperidines and/or piperazines as inhibitors of p38-alpha kinase |
| CN1147483C (zh) | 1999-04-09 | 2004-04-28 | 阿斯特拉曾尼卡有限公司 | 金刚烷衍生物 |
| US6436965B1 (en) | 2000-03-02 | 2002-08-20 | Merck Frosst Canada & Co. | PDE IV inhibiting amides, compositions and methods of treatment |
| US7273868B2 (en) | 2000-04-28 | 2007-09-25 | Tanabe Seiyaku Co., Ltd. | Pyrazine derivatives |
| HU227197B1 (en) | 2000-10-24 | 2010-10-28 | Richter Gedeon Nyrt | Nmda receptor antagonist carboxylic acid amide derivatives and pharmaceutical compositions containing them |
| HK1054390B (en) | 2000-12-22 | 2006-01-06 | Schering Corporation | Piperidine mch antagonists and their use in the treatment of obesity |
| US20030216582A1 (en) | 2001-02-08 | 2003-11-20 | Nicholas Nikolaides | 2-carboxamide-benzimidazoles useful in the treatment and prevention of ischemic reperfusion injury |
| SE0102764D0 (sv) | 2001-08-17 | 2001-08-17 | Astrazeneca Ab | Compounds |
| EP1419162A1 (en) | 2001-08-24 | 2004-05-19 | Pharmacia & Upjohn Company | Substituted-aryl 7-aza 2.2.1]bicycloheptanes for the treatment of disease |
| JP2005527472A (ja) | 2001-09-12 | 2005-09-15 | ファルマシア・アンド・アップジョン・カンパニー・エルエルシー | 疾患治療のための置換された７−アザ［２．２．１］ビシクロヘプタン |
| JP2005523237A (ja) | 2001-10-01 | 2005-08-04 | 大正製薬株式会社 | Ｍｃｈ受容体アンタゴニスト |
| JP2005523288A (ja) | 2002-02-19 | 2005-08-04 | ファルマシア・アンド・アップジョン・カンパニー・エルエルシー | 疾病治療用の縮合した二環式−ｎ−架橋−複素環式芳香族カルボキサミド |
| CA2475773A1 (en) | 2002-02-20 | 2003-09-04 | Pharmacia & Upjohn Company | Azabicyclic compounds with alfa7 nicotinic acetylcholine receptor activity |
| JP4481011B2 (ja) | 2002-03-05 | 2010-06-16 | トランス テック ファーマ，インコーポレイテッド | リガンドのｒａｇｅとの相互作用を阻害する単環式および二環式アゾール誘導体 |
| EP1500643A4 (en) | 2002-04-03 | 2007-03-28 | Dainippon Sumitomo Pharma Co | benzamidine |
| CA2484233A1 (en) | 2002-05-13 | 2003-11-27 | Eli Lilly And Company | Multicyclic compounds for use as melanin concentrating hormone antagonists in the treatment of obesity and diabetes |
| SE0202133D0 (sv) | 2002-07-08 | 2002-07-08 | Astrazeneca Ab | Novel compounds |
| KR100962972B1 (ko) | 2002-07-26 | 2010-06-09 | 주식회사유한양행 | 1-페닐피페리딘-3-온 유도체 및 그의 제조방법 |
| WO2004022536A1 (en) * | 2002-09-04 | 2004-03-18 | Glenmark Pharmaceuticals Limited | New heterocyclic amide compounds useful for the treatment of inflammatory and allergic disorders: process for their preparation and pharmaceutical compositions containing them |
| WO2004022060A2 (en) | 2002-09-06 | 2004-03-18 | Janssen Pharmaceutica, N.V. | (1h-benzoimidazol-2-yl)-(piperazinyl)-methanone derivatives and related compounds as histamine h4-receptor antagonists for the treatment of inflammatory and allergic disorders |
| BR0317230A (pt) | 2002-12-13 | 2005-10-25 | Smithkline Beecham Corp | Composto, composição, métodos de antagonizar uma atividade do receptor de quimiocina ccr-5, e de tratar uma infecção viral em um paciente, e, uso de um composto |
| TW200503994A (en) | 2003-01-24 | 2005-02-01 | Novartis Ag | Organic compounds |
| US7208491B2 (en) | 2003-02-07 | 2007-04-24 | Hoffmann-La Roche Inc. | N-monoacylated o-phenylenediamines |
| NZ541824A (en) | 2003-02-26 | 2010-04-30 | Banyu Pharma Co Ltd | Heteroarylcarbamoylbenzene derivatives as glucokinase activators |
| SI1611088T1 (sl) | 2003-04-07 | 2009-12-31 | Pharmacyclics Inc | Hidroksamati kot terapevtska sredstva |
| SE0301373D0 (sv) | 2003-05-09 | 2003-05-09 | Astrazeneca Ab | Novel compounds |
| GB0314054D0 (en) | 2003-06-17 | 2003-07-23 | Pfizer Ltd | Amide derivatives as selective serotonin re-uptake inhibitors |
| WO2005014533A2 (en) | 2003-08-08 | 2005-02-17 | Transtech Pharma, Inc. | Aryl and heteroaryl compounds, compositions, and methods of use |
| DE602004004665T2 (de) | 2003-08-20 | 2008-01-03 | Pharmacyclics, Inc., Sunnyvale | Acetylenderivate als inhibitoren von histondeacetylase |
| US7749999B2 (en) | 2003-09-11 | 2010-07-06 | Itherx Pharmaceuticals, Inc. | Alpha-ketoamides and derivatives thereof |
| CA2549009A1 (en) | 2003-12-12 | 2005-07-07 | Eli Lilly And Company | Opioid receptor antagonists |
| PE20060315A1 (es) | 2004-05-24 | 2006-05-15 | Irm Llc | Compuestos de tiazol como moduladores de ppar |
| JP4760139B2 (ja) * | 2004-05-28 | 2011-08-31 | 田辺三菱製薬株式会社 | ピロリジン誘導体およびその製法 |
| CA2566526C (en) | 2004-06-02 | 2012-10-23 | F. Hoffmann-La Roche Ag | Naphthaline derivatives useful as histamine-3-receptor ligands |
| DK1761519T3 (da) | 2004-06-21 | 2008-07-21 | Hoffmann La Roche | Indolderivater som histaminreceptorantagonister |
| JP2007277096A (ja) | 2004-07-15 | 2007-10-25 | Astellas Pharma Inc | フェネチルニコチンアミド誘導体含有医薬 |
| TW200613272A (en) | 2004-08-13 | 2006-05-01 | Astrazeneca Ab | Isoindolone compounds and their use as metabotropic glutamate receptor potentiators |
| MX2007004465A (es) | 2004-10-19 | 2007-05-07 | Hoffmann La Roche | Derivados de quinolina. |
| WO2006056848A1 (en) | 2004-11-24 | 2006-06-01 | Pfizer Limited | Octahydropyrrolo[3,4-c]pyrrole derivatives |
| JP2008521825A (ja) | 2004-11-29 | 2008-06-26 | バーテックス ファーマシューティカルズ インコーポレイテッド | ムスカリン受容体のモジュレーター |
| AR052342A1 (es) | 2004-12-21 | 2007-03-14 | Janssen Pharmaceutica Nv | Derivados sustituidos de triazolona,tetrazolona e imidazolona con actividad selectiva antagonista de alfa2c-adenoreceptores |
| BRPI0517497A (pt) | 2004-12-23 | 2008-10-07 | Chiesi Farma Spa | derivados de azol com atividade antimuscarìnica |
| WO2006091862A2 (en) | 2005-02-24 | 2006-08-31 | Kemia, Inc. | Cytokine inhibitors and their use in therapy |
| FR2884516B1 (fr) | 2005-04-15 | 2007-06-22 | Cerep Sa | Antagonistes npy, preparation et utilisations |
| EP1910290A2 (en) | 2005-06-30 | 2008-04-16 | Prosidion Limited | Gpcr agonists |
| ES2351940T3 (es) | 2005-11-18 | 2011-02-14 | F. Hoffmann-La Roche Ag | Derivados de azaindol-2-carboxamida. |
| ATE507222T1 (de) | 2005-11-30 | 2011-05-15 | Hoffmann La Roche | 1,1-dioxo-thiomorpholinyl-indolyl-methanon- derivate zur verwendung als h3-modulatoren |
| DE602006014022D1 (de) | 2005-11-30 | 2010-06-10 | Hoffmann La Roche | 5-substituierte indol-2-carbonsäureamidderivate |
| RU2008126391A (ru) | 2005-11-30 | 2010-01-10 | Ф.Хоффманн-Ля Рош Аг (Ch) | Производные 1,5-замещенного индол-2-иламида |
| KR20080074217A (ko) | 2005-12-09 | 2008-08-12 | 솔베이 파머슈티컬스 게엠베하 | 비만 및 이와 관련된 상태의 예방 또는 치료를 위한 신규의ｎ-설파모일-피페리딘아미드 |
| MX2008008339A (es) | 2005-12-21 | 2008-09-03 | Schering Corp | Derivados de anilina sustituida ùtiles como antagonistas de la histamina h3. |
| US20090018118A1 (en) | 2005-12-29 | 2009-01-15 | Uros Urleb | Heterocyclic compounds |
| WO2007098086A2 (en) * | 2006-02-17 | 2007-08-30 | Avalon Pharmaceuticals | Hydroxypiperidine derivatives and uses thereof |
| EP2032566A4 (en) | 2006-06-12 | 2009-07-08 | Merck Frosst Canada Ltd | AZETIDINE DERIVATIVES AS INHIBITORS OF STEAROYL-COENZYME-A-DELTA-9-DESATURASE |
| WO2007143824A1 (en) | 2006-06-13 | 2007-12-21 | Merck Frosst Canada Ltd. | Azacyclopentane derivatives as inhibitors of stearoyl-coenzyme a delta-9 desaturase |
| US20080085915A1 (en) | 2006-06-23 | 2008-04-10 | Cyrus Becker | Compounds and methods for the treatment of gastrointestinal and central nervous system disorders |
| TW200821303A (en) | 2006-08-08 | 2008-05-16 | Speedel Experimenta Ag | Organic compounds |
| JP2010527915A (ja) | 2007-04-26 | 2010-08-19 | アバロン ファーマシューティカルズ，インコーポレイテッド | 多重環化合物及びその用途 |
| BRPI0820171B8 (pt) | 2007-11-16 | 2021-05-25 | Rigel Pharmaceuticals Inc | compostos de carboxamida, sulfonamida e amina para distúrbios metabólicos, composição farmacêutica, e, uso dos mesmos |
| CA2707047C (en) | 2007-12-12 | 2017-11-28 | Rigel Pharmaceuticals, Inc. | Carboxamide, sulfonamide and amine compounds for metabolic disorders |
| MX2010011288A (es) | 2008-04-23 | 2010-11-09 | Rigel Pharmaceuticals Inc | Compuestos de carboxamida para el tratamiento de trastornos metabolicos. |
-
2007
- 2007-12-21 CA CA2674237A patent/CA2674237C/en active Active
- 2007-12-21 EP EP07855342.7A patent/EP2079694B1/en not_active Not-in-force
- 2007-12-21 ES ES07855342.7T patent/ES2627221T3/es active Active
- 2007-12-21 US US11/963,742 patent/US8012955B2/en active Active
- 2007-12-21 JP JP2009544239A patent/JP5650404B2/ja not_active Expired - Fee Related
- 2007-12-21 WO PCT/US2007/088742 patent/WO2008083124A1/en not_active Ceased
-
2011
- 2011-07-18 US US13/185,030 patent/US8697727B2/en active Active
-
2014
- 2014-02-25 US US14/189,638 patent/US9181220B2/en active Active
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2010514788A5 (https=) | ||
| JP2011503210A5 (https=) | ||
| JP5650404B2 (ja) | Ｎ−置換−ヘテロシクロアルキルオキシベンズアミド化合物およびその使用方法 | |
| RU2416608C2 (ru) | Ароматическое соединение | |
| JP2011506480A5 (https=) | ||
| JP2008504275A5 (https=) | ||
| CN1300114C (zh) | 苯基吡啶甲酰哌嗪衍生物 | |
| JP2011527665A5 (https=) | ||
| JP2013532692A5 (https=) | ||
| JP2017525757A5 (https=) | ||
| RU2018138047A (ru) | Гетероциклические вещества - агонисты gpr119 | |
| US20040006081A1 (en) | Pharmaceutically active piperidine derivatives, in particular as modulators of chemokine receptor activity | |
| JP2006298893A5 (https=) | ||
| RU2008116313A (ru) | Диарилминсодержащие соединения, композиции и их примеение в качестве модуляторов рецепторов с-кit | |
| JP2006509715A5 (https=) | ||
| JP2005528361A5 (https=) | ||
| JP2006500348A5 (https=) | ||
| JP2016501240A5 (https=) | ||
| EP2066659A1 (de) | Substituierte sulfonamid-derivate | |
| SK83198A3 (en) | 1-(1,2-disubstituted piperidinyl)-4-substituted piperidine derivatives as tachykinin receptor antagonists | |
| JP2010513304A5 (https=) | ||
| NZ588652A (en) | Carboxamide compounds for the treatment of metabolic disorders | |
| JP2010500391A (ja) | フェニル、ピリジン及びキノリン誘導体 | |
| JP2004203871A (ja) | 医薬組成物 | |
| CN101506202A (zh) | mGluR5调节剂Ⅰ |